Overview

Sareum's pipeline is built on the drug discovery expertise of its founders, particularly in the field of cancer.

Sareum operates a collaborative and outsourced business model. All our laboratory-based research is carried out in the laboratories of collaborators or third-party providers. This enables us to access drug discovery expertise throughout the world with a very flexible cost base.

Discovery Programmes Jun15

Click here for our latest research update

  • @Sareumplc Latest tweet

    Roche's discontinuation of its CHK1 inhibitor, RG7741 (aka Genentech's GDC-0575), means this mechanism is now a two… https://t.co/xq9zzVT44p via @Sareumplc
    View more